These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 25118790)

  • 1. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients.
    Schaefer JK; McBane RD; Black DF; Williams LN; Moder KG; Wysokinski WE
    Thromb Haemost; 2014 Nov; 112(5):947-50. PubMed ID: 25118790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
    Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
    Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
    Prandoni P; Barbar S; Milan M; Vedovetto V; Pesavento R
    Eur J Intern Med; 2014 Jan; 25(1):25-30. PubMed ID: 24120221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation.
    Pfeilschifter W; Luger S; Brunkhorst R; Lindhoff-Last E; Foerch C
    Cerebrovasc Dis; 2013; 36(2):115-9. PubMed ID: 24029592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New oral anticoagulants in the treatment of venous thromboembolic disease].
    Calvo Romero JM; Lima Rodríguez EM
    Semergen; 2013 Apr; 39(3):146-9. PubMed ID: 23540987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel oral anticoagulants: a review of new agents.
    Wanat MA
    Postgrad Med; 2013 Jul; 125(4):103-14. PubMed ID: 23933899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome.
    Malec K; Góralczyk T; Undas A
    Thromb Res; 2017 Apr; 152():93-97. PubMed ID: 27989533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P; Duraj I; Szlagowska L; Ciastkowska A; Broncel M
    Pol Merkur Lekarski; 2014 Nov; 37(221):261-4. PubMed ID: 25546985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of new oral anticoagulants in antiphospholipid syndrome.
    Arachchillage DJ; Cohen H
    Curr Rheumatol Rep; 2013 Jun; 15(6):331. PubMed ID: 23649961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of recently approved alternatives to anticoagulation with warfarin for emergency clinicians.
    Brem E; Koyfman A; Foran M
    J Emerg Med; 2013 Jul; 45(1):143-9. PubMed ID: 23375217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.